Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets

CLDWW (CLDWW)

PNK

$0.01+0.00 (+5.88%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
P/E (TTM)
EPS
Div Yield
52W Range
$0.01–$0.01
Beta
1.30

Company overview

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

29 employeeswww.calidibio.com

Peers in industry

CLDWW has no peer companies in this window.

Recent press releases

CLDWW has not issued a press release in this window.

SEC filings

All filings →

CLDWW has not filed an SEC document in this window.

CLDWW has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
147,767 sh● NEW
83,523 sh-1.7%
FMR LLC$25,755
22,013 sh+17510.4%
17,758 sh● NEW
11,491 sh● NEW
34,728 sh0.0%
10,000 sh● NEW
19,971 sh-4.1%

People at CLDWW

All people →

No officers or directors have been indexed for CLDWW.

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$5.0M
06/25
NI -$5.8M
09/25
NI -$5.1M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-2.21
Prior: $-1.99
Revenue sparkline